Autonomix Medical CEO Brad Hauser to Present at H.C. Wainwright Conference
ByAinvest
Tuesday, Sep 2, 2025 8:33 am ET1min read
AMIX--
In addition to the presentation, management will be available for one-on-one meetings with qualified investors who are registered to attend the conference. The presentation will be available via video webcast starting on September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website [1].
Autonomix's first-in-class platform system technology includes a catheter-based microchip sensing array that has the potential to detect and differentiate neural signals with greater sensitivity than currently available technologies. This technology aims to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions [2].
For more information about the conference, visit the conference website. For further details on Autonomix Medical, Inc., please visit their website at autonomix.com and connect with them on X, LinkedIn, Instagram, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142674/0/en/Autonomix-Medical-Inc-to-Present-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-to-present-at-h-c-wainwright-27th-annual-udnhxuotrunk.html
Autonomix Medical, a medical device company, announced that CEO Brad Hauser will present at the H.C. Wainwright 27th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered investors. The presentation will be webcast on-demand starting on September 8, 2025.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, has announced that its CEO, Brad Hauser, will present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8-10, 2025, in New York, NY.In addition to the presentation, management will be available for one-on-one meetings with qualified investors who are registered to attend the conference. The presentation will be available via video webcast starting on September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website [1].
Autonomix's first-in-class platform system technology includes a catheter-based microchip sensing array that has the potential to detect and differentiate neural signals with greater sensitivity than currently available technologies. This technology aims to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions [2].
For more information about the conference, visit the conference website. For further details on Autonomix Medical, Inc., please visit their website at autonomix.com and connect with them on X, LinkedIn, Instagram, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142674/0/en/Autonomix-Medical-Inc-to-Present-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.stocktitan.net/news/AMIX/autonomix-medical-inc-to-present-at-h-c-wainwright-27th-annual-udnhxuotrunk.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet